Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Deprexx is an antidepressant medication developed and manufactured by Taj Pharmaceuticals. It contains bupropion as its active ingredient, which acts as a norepinephrine-dopamine reuptake inhibitor (NDRI). By inhibiting the reuptake of these neurotransmitters, Deprexx increases their synaptic availability, thereby alleviating symptoms of major depressive disorder. It is typically administered orally as immediate-release tablets. As a generic pharmaceutical product, Deprexx serves as a therapeutic alternative to brand-name bupropion formulations for the management of clinical depression.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Deprexx.